Lead Product(s) : Cantrixil
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Vivesto
Deal Size : $1.0 million
Deal Type : Divestment
Kazia Sells IP And Trademarks Rights For Cantrixil Asset
Details : Vivesto is currently exploring TRX-E-002-1 (cantrixil), a potent and selective third generation benzopyran SMETI inhibitor, preclinically for the treatment of hematological cancers.
Product Name : TRXE-002-01
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 31, 2025
Lead Product(s) : Cantrixil
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Vivesto
Deal Size : $1.0 million
Deal Type : Divestment
Lead Product(s) : Paxalisib
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : QIMR Berghofer Medical Research Institute
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Kazia Executes Licensing Agreement with Qimr Berghofer
Details : Kazia receives an exclusive, worldwide, licence for the development of any drugs, including GDC-0084 (paxalisib) within the PI3K inhibitor class in combination with immunotherapy or PARP inhibitors.
Product Name : GDC-0084
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 09, 2024
Lead Product(s) : Paxalisib
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : QIMR Berghofer Medical Research Institute
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : CTH-401
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : $15.0 million
Deal Type : Private Placement
Cartherics Raises $15M To Advance Cell Therapy Programs
Details : The funding will support the clinical trial for CTH-401, the Company’s lead cell therapy and the only natural killer (NK) cell product currently under development for ovarian cancer.
Product Name : CTH-401
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 30, 2024
Lead Product(s) : CTH-401
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : $15.0 million
Deal Type : Private Placement
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Propanc Biopharma Hosts Corporate Update Call on Recent Progress and Positive Results
Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.
Product Name : PRP
Product Type : Protein
Upfront Cash : Inapplicable
February 22, 2024
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.
Product Name : PRP
Product Type : Protein
Upfront Cash : Inapplicable
August 15, 2023
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluorouracil,Calcium Folinate,Oxaliplatin
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Allarity Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the Agreement, Allarity will support FivepHusion’s future clinical development of Deflexifol (5-fluorouracil) for the treatment of solid tumors by using certain of Allarity’s drug-specific DRP® companion diagnostics, including its validated DR...
Product Name : Deflexifol
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
July 31, 2023
Lead Product(s) : Fluorouracil,Calcium Folinate,Oxaliplatin
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Allarity Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Peter MacCallum Cancer Centre
Deal Size : Undisclosed
Deal Type : Partnership
Propanc Biopharma Announces Strategic Pharma Partnering Initiative
Details : The partnership aims for Propanc's lead product candidate, PRP (pancreatic proenzyme), a mixture of two proenzymes, trypsinogen and chymotrypsinogen, advancing towards a Phase I, first-in-human study in advanced cancer patients.
Product Name : PRP
Product Type : Protein
Upfront Cash : Undisclosed
June 06, 2023
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Peter MacCallum Cancer Centre
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : AMP945,Fluorouracil,Calcium Folinate
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in Model of Pancreatic Cancer
Details : AMP945 (narmafotinib) is an orally bioavailable small molecule with a best-in-class profile. Amplia’s highly selective FAK inhibitor AMP945, when used in combination with FOLFIRINOX, enhances survival in a preclinical model of pancreatic cancer.
Product Name : AMP945
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 29, 2023
Lead Product(s) : AMP945,Fluorouracil,Calcium Folinate
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HaemaLogiX To Present Final Data from Anti-KMA CAR-T Preclinical Studies At AACR
Details : Anti-KMA CAR-T is a myeloma-specific antigen not found on normal cells. It has completed preclinical studies and is being developed to treat kappa-type multiple myeloma.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 27, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : n.c.a. 177-Lu
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : SHINE Technologies
Deal Size : Undisclosed
Deal Type : Agreement
Details : The isotope will be used by Radiopharm in the development of its clinical pipeline of diagnostic and therapeutic radiopharmaceutical products including RAD206. Lu-177 is an important isotope utilized in multiple programs across Radiopharm’s portfolio.
Product Name : RAD206
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 19, 2022
Lead Product(s) : n.c.a. 177-Lu
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : SHINE Technologies
Deal Size : Undisclosed
Deal Type : Agreement